Literature DB >> 7161316

Intracellular accumulation of a fluorescent derivative of paromomycin in human fibroblasts.

J H Buchanan, S I Rattan, A Stevens, R Holliday.   

Abstract

Human fetal lung fibroblasts grown in the presence of dansyl-paromomycin (DNS-Pm), a fluorescent derivative of the aminoglycoside antibiotic, paromomycin, probably accumulate DNS-Pm in the lysosomes. The intracellular concentration of DNS-Pm is proportional to the extracellular concentration and to the length of time cells are exposed to the compound. The accumulation of DNS-Pm by human fibroblasts continued to increase for several days, reaching a saturation after 7 days. The kinetic data are consistent with the establishment of a steady state in the cell between fluid-phase pinocytosis and exocytosis of DNS-Pm. About 80% of the intracellular DNS-Pm ws released in 24 hr when fresh medium without the analogue was added. The residual 20% remained within the cells, suggesting that it may be irreversibly bound to the lysosomes, endoplasmic reticulum, or ribosomes. The uptake of paromomycin by cells in culture may be a useful means to study error propagation during growth and lifespan of cells in vitro.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7161316     DOI: 10.1002/jcb.240200108

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  3 in total

1.  Hygromycin B therapy of a murine coronaviral hepatitis.

Authors:  G Macintyre; B Curry; F Wong; R Anderson
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

2.  Inherent resistance of HeLa cell derivatives to paromomycin.

Authors:  C L Bunn; J I Baron; D Mitchell
Journal:  In Vitro Cell Dev Biol       Date:  1986-07

3.  Paromomycin and geneticin inhibit intracellular Cryptosporidium parvum without trafficking through the host cell cytoplasm: implications for drug delivery.

Authors:  J K Griffiths; R Balakrishnan; G Widmer; S Tzipori
Journal:  Infect Immun       Date:  1998-08       Impact factor: 3.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.